Reported Earlier, FDA Approves Amgen's IMDELLTRA (tarlatamab-dlle) The First And Only T-Cell Engager Therapy For The Treatment Of Extensive-Stage Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Amgen's IMDELLTRA (tarlatamab-dlle), the first T-cell engager therapy for extensive-stage small cell lung cancer (ES-SCLC). The approval is based on a 40% objective response rate and a 9.7-month median duration of response observed in clinical studies.
May 17, 2024 | 6:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FDA approval of Amgen's IMDELLTRA for ES-SCLC is a significant milestone, likely to boost investor confidence and positively impact the stock price in the short term.
The FDA approval of IMDELLTRA is a major regulatory milestone for Amgen, likely to enhance its market position in oncology. The impressive clinical trial results (40% objective response rate, 9.7-month median duration of response) further support the potential for increased revenue from this new therapy.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100